Protalix BioTherapeutics, Inc. (DE) Common Stock (PLX)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Aug 14, 2026Investment Snapshot
- Trading 7% below Graham Number — thin margin of safety
- Piotroski F-Score 4/9 — moderate financial health
- Strong ROE of 34.5% with 28.2% net margin
Protalix BioTherapeutics, Inc. (DE) Common Stock (PLX) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the AMEX , with a market capitalisation of $185 million . Key value metrics: P/E ratio 7.5, P/B ratio 2.60, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Protalix BioTherapeutics, Inc. (DE) Common Stock — Fundamental Analysis Summary
Protalix BioTherapeutics, Inc. (DE) Common Stock (PLX) is trading 7% below its Graham Number of $2.47, offering a thin margin of safety. The stock carries a low trailing P/E ratio of 7.5x.
On financial health, PLX shows a moderate Piotroski F-Score of 4/9, and strong return on equity of 34.5% (sector average: -20.1%), and manageable leverage with a debt-to-equity ratio of 0.55.
StockPik's composite Value Score for PLX is 89/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
PLX reports a high gross margin of 70.1% (sector average: 37.4%) and a strong operating margin of 33.4%.
PLX shows revenue declining at 1% year-over-year, with earnings declining at 325%.